Publicacións en colaboración con investigadores/as de Policlinico S.Orsola-Malpighi (24)

2024

  1. A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 10, Núm. 4, pp. 285-293

  2. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  3. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

  4. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

    Transplant International , Vol. 37

  5. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 10, pp. 1529-1628.e54

  6. Molecular states associated with dysfunction and graft loss in heart transplants

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 3, pp. 508-518

  7. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival

    American Journal of Transplantation, Vol. 24, Núm. 8, pp. 1414-1426

2023

  1. Impact of lymph node ratio and number of lymph node metastases on survival and recurrence in laryngeal squamous cell carcinoma

    Head and Neck, Vol. 45, Núm. 9, pp. 2274-2293

  2. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 4, pp. 457-468

2022

  1. Assessing the Relationship Between Molecular Rejection and Parenchymal Injury in Heart Transplant Biopsies

    Transplantation, Vol. 106, Núm. 11, pp. 2205-2216

  2. Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 79, Núm. 20, pp. 1986-1997

  3. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  4. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

  5. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator

    European heart journal, Vol. 43, Núm. 32, pp. 3053-3067

  6. Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study

    Frontiers in Cardiovascular Medicine, Vol. 10

  7. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy

    Circulation. Arrhythmia and electrophysiology, Vol. 15, Núm. 5, pp. e010075

  8. The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy

    European Journal of Preventive Cardiology, Vol. 29, Núm. 4, pp. 645-653

2021

  1. Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: The ESC EORP Cardiomyopathy/Myocarditis Registry

    European Heart Journal Cardiovascular Imaging, Vol. 22, Núm. 7, pp. 781-789

  2. Prospective follow-up in various subtypes of cardiomyopathies: Insights from the ESC EORP Cardiomyopathy Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 7, Núm. 2, pp. 134-142

  3. Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging

    Journal of Clinical Medicine, Vol. 10, Núm. 16